Hygromycin B
Hygromycin B, an aminoglycoside antibiotic derived from Streptomyces hygroscopicus, exerts its cytotoxic effects by disrupting protein synthesis in bacteria, fungi, and eukaryotic cells. Due to its broad-spectrum activity, it is widely employed for selecting both prokaryotic and eukaryotic transformed with hygromycin resistance gene.
Hygromycin B kills cells by binding to ribosomes and blocking protein synthesis. Resistance is conferred by the hygRgene, which produces an enzyme that inactivates the antibiotic through phosphorylation. To establish optimal working conditions, it is needed to perform a kill curve to identify the minimum concentration required to eliminate non-resistant cells.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 527.5 |
| Cas No. | 31282-04-9 |
| Formula | C20H37N3O13 |
| Solubility | ≥26.38 mg/mL in H2O; ≥5.35 mg/mL in EtOH; ≥9.14 mg/mL in DMSO |
| Chemical Name | (3'R,3aS,4S,4'R,5'R,6R,6'R,7S,7aS)-4-[(1R,2S,3R,5S,6R)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy-6'-[(1S)-1-amino-2-hydroxyethyl]-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-2,2'-oxane]-3',4',5',7-tetrol |
| SDF | Download SDF |
| Canonical SMILES | CNC1CC(C(C(C1O)OC2C3C(C(C(O2)CO)O)OC4(O3)C(C(C(C(O4)C(CO)N)O)O)O)O)N |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment:[1] | |
|
Cell lines |
Mouse L cells |
|
Reaction Conditions |
200 μg/ml hygromycin B for 2 ~ 6 weeks |
|
Applications |
Hygromycin B was used for resistance selection in mouse L cells transfected withEscherichia coli genes coding for resistance to the aminocyclitol antibiotics hygromycin B. |
| Animal experiment:[2] | |
|
Animal models |
Four-week-old BALB/c mice susceptible to MHV-A59 infection |
|
Dosage form |
0 ~ 10 μmol/kg Intraperitoneal (i.p.) injection |
|
Applications |
A single injection of hygromycin B reduced the number of lesions in the livers of MHV-A59-inoculated mice. Higher doses of the drug appeared to be slightly more effective at reducing virus-induced lesions. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Santerre RF, Allen NE, Hobbs JN Jr, et al. Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells. Gene, 1984, 30(1-3): 147-156. 2. Macintyre G, Curry B, Wong F, et al. Hygromycin B therapy of a murine coronaviral hepatitis. Antimicrobial Agents and Chemotherapy, 1991, 35(10): 2125-2127. |
|
Quality Control & MSDS
- View current batch:
Chemical structure
